Clinical utility and limitations of FDG PET in detecting recurrent hepatocellular carcinoma in postoperative patients

International Journal of Clinical Oncology

Volumn 19, Issue 6, 2014, Pages 1020-1028

  Hayakawa, Nobuyuki ^a   Nakamoto, Yuji ^a   Nakatani, Koya ^a   Hatano, Etsuro ^a   Seo, Satoru ^a   Higashi, Tatsuya ^b   Saga, Tsuneo ^c   Uemoto, Shinji ^a   Togashi, Kaori ^a  

^a KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Shiga Medical Center Research Institute   (Japan)

^c NATIONAL INSTITUTE OF RADIOLOGICAL SCIENCES   (Japan)

Author keywords

FDG PET; Hepatocellular carcinoma; Prognostic value; Recurrence; Surgery

Indexed keywords

FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; CARCINOMA, HEPATOCELLULAR; DIAGNOSTIC USE; FEMALE; HUMAN; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; POSTOPERATIVE PERIOD; PROCEDURES; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, HEPATOCELLULAR; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; POSITRON-EMISSION TOMOGRAPHY; POSTOPERATIVE PERIOD; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY;

EID: 84917732551     PISSN: 13419625     EISSN: 14377772     Source Type: Journal    
DOI: 10.1007/s10147-013-0653-3     Document Type: Article

References (31)

1. Ferlay J, Shin H-R, Bray F et al (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127:2893–2917
2. Lau W, Lai ECH (2008) Management and recent advances. Hepatobiliary Pancreat Dis Int 7:237–257
3. Omata M, Lesmana LA, Tateishi R et al (2010) Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int 4:439–474
4. Trojan J, Schroeder O, Raedle J et al (1999) Fluorine-18 FDG positron emission tomography for imaging of hepatocellular carcinoma. Am J Gastroenterol 94:3314–3319
5. Khan MA, Combs CS, Brunt EM et al (2000) Positron emission tomography scanning in the evaluation of hepatocellular carcinoma. J Hepatol 32:792–797
6. 18F-FDG positron emission tomography/computed tomography for detecting recurrence of hepatocellular carcinoma in posttransplant patients. Liver Transpl 16:767–772
7. 18F-FDG PET after radiofrequency ablation therapy. Oncol Rep 18:1469–1473
8. 18F-FDG PET/CT. World J Hepatol 1:90–97
9. Lin C-Y, Chen J-H, Liang J-A et al (2011) 18F-FDG PET or PET/CT for detecting extrahepatic metastases or recurrent hepatocellular carcinoma: a systematic review and meta-analysis. Eur J Radiol 81:2417–2422
10. Taketomi A, Toshima T, Kitagawa D et al (2010) Predictors of extrahepatic recurrence after curative hepatectomy for hepatocellular carcinoma. Ann Surg Oncol 17:2740–2746
11. Ochiai T, Ikoma H, Okamoto K et al (2012) Clinicopathologic features and risk factors for extrahepatic recurrences of hepatocellular carcinoma after curative resection. World J Surg 36:136–143
12. Tanaka K, Shimada H, Matsuo K et al (2008) Clinical features of hepatocellular carcinoma developing extrahepatic recurrences after curative resection. World J Surg 32:1738–1747
13. Flamen P, Stroobants S, Van Cutsem E et al (1999) Additional value of whole-body positron emission tomography with fluorine-18-2-fluoro-2-deoxy-d-glucose in recurrent colorectal cancer. J Clin Oncol 17:894–901
14. Keidar Z, Haim N, Guralnik L, Wollner M (2004) PET/CT using 18F-FDG in suspected lung cancer recurrence: diagnostic value and impact on patient management. J Nucl Med 45:1640–1646
15. Chung HH, Jo H, Kang WJ et al (2007) Clinical impact of integrated PET/CT on the management of suspected cervical cancer recurrence. Gynecol Oncol 104:529–534
16. Chen Y-K, Hsieh D-S, Liao C-S et al (2005) Utility of FDG-PET for investigating unexplained serum AFP elevation in patients with suspected hepatocellular carcinoma recurrence. Anticancer Res 25:4719–4725
17. 18F-FDG PET in the detection of extrahepatic metastases from hepatocellular carcinoma. J Gastroenterol 39:961–968
18. Nagaoka S, Itano S, Ishibashi M et al (2006) Value of fusing PET plus CT images in hepatocellular carcinoma and combined hepatocellular and cholangiocarcinoma patients with extrahepatic metastases: preliminary findings. Liver Int 26:781–788
19. ®-enhanced ultrasound, gadolinium diethylene-triamine-pentaacetic acid-enhanced magnetic resonance imaging, and contrast-enhanced computed tomograph. Oncology 81:66–72
20. Ho C-M, Lee P-H, Shau W-Y et al (2012) Survival in patients with recurrent hepatocellular carcinoma after primary hepatectomy: comparative effectiveness of treatment modalities. Surgery 151:700–709
21. Liu L, Miao R, Yang H et al (2012) Prognostic factors after liver resection for hepatocellular carcinoma: a single-center experience from China. Am J Surg 203:741–750
22. Colli A, Fraquelli M, Casazza G et al (2006) Accuracy of ultrasonography, spiral CT, magnetic resonance, and alpha-fetoprotein in diagnosing hepatocellular carcinoma: a systematic review. Am J Gastroenterol 101:513–523
23. Hu Z, Zhou J, Xu X et al (2012) Salvage liver transplantation is a reasonable option for selected patients who have recurrent hepatocellular carcinoma after liver resection. PLoS ONE 7:e36587
24. Chua TC, Morris DL (2012) Exploring the role of resection of extrahepatic metastases from hepatocellular carcinoma. Surg Oncol 21:95–101
25. Torizuka T, Tamaki N, Inokuma T et al (1995) In vivo assessment of glucose metabolism in hepatocellular carcinoma with FDG-PET. J Nucl Med 36:1811–1817
26. Seo S, Hatano E, Higashi T et al (2007) Fluorine-18 fluorodeoxyglucose positron emission tomography predicts tumor differentiation, P-glycoprotein expression, and outcome after resection in hepatocellular carcinoma. Clin Cancer Res 13:427–433
27. Okuda K, Tanakab M, Nakayamaa T et al (1993) Clinicopathologic comparison between resected hepatocellular carcinomas (HCC) and recurrent tumors: a special reference to multicentric carcinogenesis of HCC. Int Hepatol Commun 1:65–71
28. Hatano E, Ikai I, Higashi T et al (2006) Preoperative positron emission tomography with fluorine-18-fluorodeoxyglucose is predictive of prognosis in patients with hepatocellular carcinoma after resection. World J Surg 30:1736–1741
29. Higashi T, Hatano E, Ikai I et al (2010) FDG PET as a prognostic predictor in the early post-therapeutic evaluation for unresectable hepatocellular carcinoma. Eur J Nucl Med Mol Imaging 37:468–482
30. Lee JH, Park JY, Kim DY et al (2011) Prognostic value of 18F-FDG PET for hepatocellular carcinoma patients treated with sorafenib. Liver Int 31:1144–1149
31. Kitamura K, Hatano E, Higashi T et al (2011) Proliferative activity in hepatocellular carcinoma is closely correlated with glucose metabolism but not angiogenesis. J Hepatol 55:846–857